Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC737754)

Next Previous
Search
Trial Profile

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC737754)

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary) ; Doxorubicin; Ifosfamide
  • Indications Alveolar soft part sarcoma; Cancer metastases; Carcinoma; Chondrosarcoma; Clear cell sarcoma; Fibroma; Haemangiosarcoma; Histiocytoma; Leiomyosarcoma; Liposarcoma; Liver cancer; Malignant fibrous histiocytoma; Muscle tissue neoplasms; Nerve sheath neoplasms; Osteosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PAZNTIS

    • Most Recent Events

    • 31 Jul 2023 Results (As of December 31, 2021, n=85) assessing assessing Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma published in the Journal of Clinical Oncology
    • 27 Mar 2023 Results(n=85 from dose-finding and randomized arms of ARST1321) assessing wound complications following addition of pazopanib, a tyrosine kinase inhibitor (TKI), to neoadjuvant radiotherapy (RT) +/- chemotherapy for soft tissue sarcoma published in the Journal of Surgical Oncology
    • 07 Jun 2022 Results assessing outcomes following preoperative chemoradiation plus minus pazopanib in non-rhabdomyosarcoma soft tissue sarcoma presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top